---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-046010"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T06:56:20.573530+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Roivant Sciences raises ~$200M via registered direct offering of 19.6M shares at $10.21

## Summary
- Sold 19,600,685 common shares at $10.21 each for aggregate gross proceeds of ~$200.1 million.
- Net proceeds to be used for investment into subsidiary Immunovant, Inc. and for working capital and general corporate purposes.
- Offering made pursuant to prospectus supplement under effective shelf registration statement (Form S-3).

## SEC filing metadata
- accession: 0001140361-23-046010
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123046010/0001140361-23-046010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123046010/ny20011553x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-046010
- JSON: https://secwatch.observer/filing/0001140361-23-046010.json
- Plain text: https://secwatch.observer/filing/0001140361-23-046010.txt

## Key facts
- Material Agreements
  Roivant Sciences Ltd. entered into Purchase and Sale Agreements with certain institutional investors valued at aggregate gross proceeds of approximately $200.1 million (effective 2023-09-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: aggregate gross proceeds of approximately $200.1 million
  - Effective: 2023-09-26
  source text: On September 26, 2023, Roivant Sciences Ltd. (the “Company”) entered into common share purchase and sale agreements (collectively, the “Purchase and Sale Agreements”) with certain institutional investors, pursuant to which the Company agreed to issue and sell an aggregate of 19,600,685 of the Company’s common shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123046010/0001140361-23-046010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.